Compugen Ltd

CGENNASDAQ NMS - GLOBAL MARKET

Health CareBiotechnology

$2.63

-0.150000 (-5.40%)

As of 05/29/26 EDT · USD

Compare

52-Week Low: $1.30Current: $2.6352-Week High: $3.24

Key Statistics

Open

$2.77

Day High

$2.77

Day Low

$2.63

Prev. Close

$2.78

Volume

367.56K

Avg. Volume

—

Market Cap

$248.68M

P/E (TTM)

7.27

Forward P/E

—

P/B Ratio

—

52W High

$3.24

52W Low

$1.30

50D MA

$2.60

200D MA

$1.92

Dividend Yield

—

Beta

—

Performance

+0.8%

+1.2%

+65.4%

YTD

+69.7%

+75.3%

About

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

cgen.com/